# Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease

> **NCT00742716** · PHASE2 · COMPLETED · sponsor: **OPKO IP Holdings II, Inc.** · enrollment: 41 (actual)

## Conditions studied

- Chronic Kidney Disease
- Secondary Hyperparathyroidism
- Chronic Renal Insufficiency
- Chronic Renal Failure

## Interventions

- **DRUG:** CTA018 Injection

## Key facts

- **NCT ID:** NCT00742716
- **Lead sponsor:** OPKO IP Holdings II, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2010-02
- **Final completion:** 2010-06
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2014-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00742716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00742716, "Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00742716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*